Disease Management in Patients with Delirium

Thomas Jochum\(^1\) and Karl-Jürgen Bär\(^*\),\(^2\)

\(^1\)Department of Psychiatry and Psychotherapy, Straße des Friedens 122, SRH Waldklinikum, Gera 07548, Germany
\(^2\)Department of Psychiatry and Psychotherapy, Philosophenweg 3, University Hospital, Jena 07749, Germany

Abstract: Delirium occurs as a pathophysiological state in connection with various diseases, particularly among patients in critical care. Since it may be a life-threatening condition, any physician should be able to initiate correct assessment and treatment of delirium. This review summarizes current knowledge on care of patients with delirium.

The symptoms of delirium contain primarily disturbance of consciousness, attention, cognition, and perception and may comprise disturbance of psychomotor activity, emotions, and sleep. High prevalence of delirium is observed in critically ill patients in intensive care units. It is thus necessary to monitor the comorbid conditions when patients are diagnosed with delirium, especially since delirium is a prognostic factor for rise in morbidity and mortality. The identification of underlying aetiology of delirium and immediate intervention and treatment for urgent general medical conditions should be in the focus, and should be paralleled by measures ensuring patient’s safety and continuous monitoring.

Somatic interventions depend on underlying aetiology, and patient’s clinical as well as comorbid conditions, but they mainly consist of treatment with high-potency neuroleptic drugs such as haloperidol. Interventions which reduce or eliminate environmental factors contributing to an exacerbation and maintenance of delirium are strongly recommended. Eventually, it is important to establish and maintain psychological support to the patient and his family regarding illness, including post-delirium management.

Keywords: Delirium, treatment, psychiatric, assessment, aetiology.

1. CLINICAL FEATURES

Delirium is defined as an acute, severe and principally reversible organic brain syndrome of different aetiology. Clinical features of delirium include disturbances of consciousness, attention, cognition, perception, thinking, emotions, wake-sleep rhythm, and psychomotor activity. Symptoms develop over hours to days and they tend to fluctuate during the course of the disease. Some patients suffer from prodromal symptoms such as restlessness, anxiety, irritability or sleep disturbance 1 to 3 days before the onset of full-blown delirium. While symptoms typically last for 10 to 12 days, durations from less than 1 week to more than 2 months is possible [1-7].

Definition

According to the International classification of diseases, diagnosis of delirium can be made when the following criteria are fulfilled [8]:

1. Disturbance of attention and consciousness with reduced ability to focus, sustain, or shift attention up to stupor or coma.
2. Global disturbance of cognition (illusions, hallucinations, most often visual), perception, delusional ideas, alteration of especially recent memory and abstract thinking, incoherence, disorientation (most often to time or place), language and speech disturbances (dysarthria, visuo-constructional impairment).
3. Disturbance of psychomotor activity (hypo – or hyperactivity, prolonged reaction time, increase startle response, logorrhea and mutism).
4. Disturbance of wake-sleep rhythm (e.g. inversion of wake-sleep-rhythm, nightmares, daytime sleepiness, night-time agitation, sleep discontinuity).
5. Affective symptoms like anxiety, fear, depression, irritability, euphoria, anger and apathy. Patients may also show emotional lability.

If those symptoms cannot be better explained by pre-existing dementia and represent sudden decline from previous functioning level, the diagnosis of delirium can be made. The diagnosis is substantiated if evidence exists from the patient’s history, physical examination, or from laboratory tests. Most often the delirium is a consequence of severe general medical condition, substance intoxication or withdrawal, use of medication, toxin exposure or combination of these factors.

Epidemiology

Prevalence of delirium in hospitalised medically ill ranges from 10 to 30% in younger patients [9] and reaches up to 65% in the hospitalised elderly [10]. About 50% of postoperative patients (especially patients who just underwent cardiotomy, hip surgery, or transplant) [11, 12], 28-48% of patients with advanced cancer upon admission to acute hospital or hospice [13], and 85% up to 90% of patients in days and hours before death develop delirium [14, 15]. There is also an increased risk to develop delirium for patients with burns and patients who receive dialysis [16, 17].
or suffering from chronic liver diseases [18]. Furthermore, approximately 30-40% of hospitalized AIDS patients develop delirium [19-21]. In postoperative patients (especially after orthopaedic surgery), delirium is an indication for postoperative complications, longer postoperative recuperation periods, longer hospital stays, and long-term disability [22-24].

Delirium can appear at every age, but it is most often observed in patients older than 60 years [3]. Delirium can occur in parallel with dementia and is one of the important differential diagnoses besides affective disorder in the elderly patient [25, 26]. The most common issue in differential diagnosis here is to determine whether patient has dementia rather than delirium. It is also possible that delirium is superimposed on pre-existing dementia. The temporal course and reversibility of symptoms of cognitive deficiency are helpful in distinguishing between delirium and dementia. Patients with delirium typically show fluctuating symptoms over a time period of 24 h, including consciousness, whereas these symptoms usually appear unaltered in patients with dementia [25].

Clinical Picture

From the practical point of view, it seems to be of interest that some authors differentiate delirium in two different subtypes according to psychomotor activity. These delirium subtypes include hyperactive (agitated, hyper alert) subtype, the hypoactive (lethargic, hypo alert) and mixed subtype [27]. The hyperactive form is thought to occur with hallucinations, delusions or illusions, whereas the hypoactive form is characterised by confusion and sedation. The delirious patient may also exhibit neurological abnormalities (e.g. tremor, myoclonus, nystagmus, ataxia, asterixis, cranial nerve palsies and reflex or muscle tone changes) depending on aetiology [18]. EEG background rhythm is typically showing generalised slowing, except in alcohol or sedative withdrawal syndrome with delirium, where EEG shows fast activity [28]. Several screening instruments have been designed to screen for delirium symptoms among patients by nursing stuff (e.g., Clinical Assessment of Confusion-A, Confusion Rating Scale, Confusion Assessment Method, see appendix 1) [18].

Long-Term Outcome

In general, delirium in the medically ill and elderly patients is associated with significant morbidity and mortality [29, 30]. Patients with delirium have 25% chance to die within the following 6 months [31]. In the presence of delirium on admission to the hospital the mortality rate was found to be 22%-76% in elderly patients [29, 32]. Delirium, particularly if untreated, may progress to stupor, coma, seizures, or death. Seizures can occur as a complication among patients with delirium due to alcohol or sedative withdrawal, cocaine intoxication, hypoglycaemia, strokes, head trauma, or extensive burns [18].

Most patients who suffer from delirium recover within 4 weeks or shorter period of time, but a fluctuating course up to 6 months is possible. An important risk factor for the prolonged course of delirium is age, as elderly patients frequently show symptom durations exceeding 1 month [18, 33]. Full recovery is also less likely in the elderly, although symptoms may be due to pre-existing dementia. Additionally, elderly patients have significantly increased risk of developing complications, such as pneumonia and decubitus ulcers [34].

2. UNDERLYING AETIOLOGIES

Because delirium is potentially life threatening, it is absolutely necessary to perform careful and comprehensive assessment of general medical and mental state of the patient. Although clinical presentation of delirium is quite common, the underlying aetiologies differ. When assessing the potential diagnosis of delirium, clear organic aetiology is the most probable cause [5] but several environmental factors appear to increase the severity of symptoms of delirium [35]. Since about 44% of the critically ill and elderly hospitalised patients show multiple aetiologies for delirium [36], careful clinical observation is the most important measure for the treating clinicians [18]. Aetiologies that can be causes for delirium are detailed below (see table 1).

Delirium due to General Medical Condition

Delirium can be associated with many different general medical conditions. Some of them have typical clinical and paraclinical findings, which can be helpful for diagnosis of underlying medical disturbance. In general, underlying condition can be central nervous system disorders, metabolic disorders, cardiopulmonary disorders and systemic illnesses.

Delirium due to Substance Use or Withdrawal

Substances that are not usually regarded as having psychoactive properties as well as those with established psychoactive properties are able to cause delirium due to substance use or withdrawal [37]. Delirium that occurs during substance intoxication may arise within minutes to hours. Potential for causing delirium is much higher when drugs having anticholinergic activity are combined [38]. With decreasing intoxication, delirium generally ends within hours or a few days after intoxication [18]. In the case of substance withdrawal, delirium develops after reduction of sustained high dose use or when clearance of a certain substance is improved. Substance withdrawal delirium may last only a few hours or may persist for as long as 2-4 weeks. Longer acting substances are usually associated with less severe but more protracted delirium [18]. The following substances (including substances of abuse, prescription medication, toxins) are associated with delirium:

1) Drugs of abuse: Alcohol, amphetamines, cannabis, cocaine, opioids, hypnotics, sedatives, inhalants, hallucinogens, phencyclidine,
2) Medications: Anaesthetics, analgesics, antiasthmatic drugs, antihistamines, anticonvulsants, antihypertensive and cardiovascular medications, antimicrobials, antiparkinsonian medications, corticosteroids, gastrointestinal medication, muscle relaxants, immunosuppressive agents, lithium and anticholinergic psychotropic medications,
3) Toxins: Anticholinesterase, organophosphate insecticides, carbon monoxide and dioxide, volatile substances such as fuel and organic solvents.
3. TREATMENT RATIONALES

Assessment and General Aspects of Treatment

Treatment of delirium involves combination of pharmacological, environmental and supportive interventions. An appropriate treatment must combine interventions in order to identify and correct the underlying causes with interventions that relieve current symptoms. The physician caring for the patient should coordinate with other specialists (internist, neurologist, surgeon, psychiatrist etc.) to ensure a comprehensive assessment and treatment. The goal of diagnosis is to discover reversible causes of delirium and prevent complications by prompt treatment of these specific disorders [18, 26].

First steps in identifying aetiology are a careful review of patient's medical history and medication, including general medical or anaesthesia records (if postoperative), physical, neurological and psychiatric examination, and an interview of family members or other persons close to the patient. Blood chemistries (electrolytes, glucose, calcium, albumin, blood urea nitrogen, creatinine, SGOT, SGPT, bilirubin, alkaline phosphatase, magnesium, PO₂), complete blood count, electrocardiogram, chest-X-ray, arterial blood gases, and urine analysis are indicated for all patients suffering from delirium.

| Central nervous system disorders | vascular disease (ischemic stroke, subdural haematoma, subarachnoid haemorrhage, intracranial bleeding) |
|                               | hypertensive encephalopathy |
|                               | head trauma |
|                               | seizure (post-ictal state, non-convulsive status epilepticus) |
|                               | meningitis/meningo-encephalitis (bacterial, viral, septic metastatic, abscess of the brain, HIV, mycosis etc.) |
|                               | septic encephalopathy |
|                               | degenerative disease |
| Metabolic disorders           | renal failure |
|                               | hepatic failure |
|                               | anaemia |
|                               | hypoxia |
|                               | hypoglycaemia |
|                               | thiamine deficiency |
|                               | endocrinopathy |
|                               | fluid imbalance |
|                               | electrolyte imbalance |
|                               | acid-base imbalance |
| Cardio-pulmonary disorders    | myocardial infarction |
|                               | congestive heart failure |
|                               | cardiac arrhythmia |
|                               | shock |
|                               | respiratory failure |
| systemic illnesses            | Substance intoxication |
|                               | Substance withdrawal |
|                               | postoperative state |
|                               | infection |
|                               | neoplasm |
|                               | severe trauma |
|                               | temperature dysregulation |

Additional investigations should be organized as stag-to-stage diagnostic measures if they are clinically indicated and practicable: blood and urine culture, drug screen and serum levels of medications (e.g. theophylline, cyclosporine, digitoxine) as well as special blood tests (ammonia, venereal disease research laboratory, folate, B₁, B₆ and B₁₂ levels, heavy metal screen, lupus erythematosus prep, antinuclear antibodies, urinary porphyrins, HIV) should be done following clinical suspicion. If cerebral trauma, tumour, metastases, neurovascular or infectious diseases are thought to be possible causes of delirium, computerized brain tomography (CT) or magnetic resonance imaging (MRI) must be done. If central nervous infection is considered lumbar puncture and analysis of cerebrospinal fluid are mandatory. Finally, electroencephalogram (EEG) could clarify if an epileptic seizure (especially non-convulsive status epilepticus) is responsible for the delirious symptomatology. Neuro-imaging, lumbar puncture and EEG also should be done always if the cause of delirium remains unclear, especially in younger patients.

Immediate Interventions

Interventions for acute conditions should be initiated in parallel to the diagnostic process. Vital signs, fluid intake and output, and levels of oxygenation must be continuously monitored as delirium can be a sign for life-threatening general medical condition [18]. Generally, nonessential
medications should be discontinued, and doses of necessary medication should be kept as low as possible. The following measures should be taken depending on symptoms and aetiology:

- In hypoxia or anoxia, immediate oxygen delivery is indicated. This can be the case in context of pneumonia, obstructive or restrictive pulmonary or cardiac disease, hypotension, severe anaemia, or carbon monoxide poisoning.
- Diagnosis of hypoglycaemia can be confirmed by blood and urine tests. It can be easily treated with 50 mg 50% glucose and 100 mg thiamine hydrochloride i.v. (before glucose).
- Hypertension of 250/150 mmHg should lead to prompt antihypertensive treatment, for instance with clonidine.
- Alcohol or sedative withdrawal must be treated appropriately with substituting drugs and neuroleptics (diazepam plus haloperidol), reduced according to a schedule and complemented completed with thiamine hydrochloride initially i.v.
- Patients with Wernicke’s encephalopathy require urgent treatment with 100 mg i.v. thiamine hydrochloride followed by daily administration of the drug.
- In anticholinergic delirium, withdrawal of offending agents is indicated. In severe cases administration of physostigmine should be considered unless contraindicated.
- In the context of psychopathology, suicidal tendencies and potential for violence must be assessed and if necessary interventions for risk minimization have to be taken (removal of dangerous items, increase in supervision, pharmacotherapy).

Assuring patient’s safety also includes reducing risk for self-harm through falls, wandering etc. Patients who are restrained must be observed continuously, and restraints as well as their justification must be documented. Restraints themselves can increase agitation and carry risk for injuries. If possible, other protection such as sitters should be chosen. Regular monitoring will also allow for the adjustment of treatments, as it may indicate effectiveness of interventions [18].

**Somatic Interventions**

**Antipsychotics**

Numerous case reports and uncontrolled trials have provided evidence for efficacy of antipsychotics in treatment of delirium. Haloperidol, a high potency dopamine-blocking agent with few or no anticholinergic effects, minimal cardiovascular side effects, and no active metabolites, has generally been considered the antipsychotic medication of first choice for treatment of delirium [18, 39, 40]. Although haloperidol is the most studied pharmacological treatment, there has been an increasing use of risperidone in recent years [26, 41]. However, new antipsychotic medications such as risperidone, olanzapine, quetiapine etc. have not been studied intensively [42-44]. Studies have demonstrated superiority of antipsychotic medication over benzodiazepines in delirium treatment [45]. In patients treated with neuroleptics, improvement in delirium symptoms can be observed quickly and before interventions directed at medical aetiology of this delirium are initiated [40].

On the basis of doses used in several studies, starting haloperidol in range of 1-2 mg every 2-4 hours has been suggested for young adults and low doses (0.25-0.50 mg haloperidol every 4 hours) are recommended for elderly patients [18, 46, 47]. Titration to higher doses may be required for patients who continue to be agitated. Even bolus intravenous haloperidol doses exceeding 50 mg with total daily dose up to 500 mg have been reported and were associated with minimal effects on heart rate, blood pressure, and minimal extrapyramidal side effects [18, 48].

The most important side effects in the use of haloperidol are extrapyramidal effects, tardive dyskinesia and lengthening of QT interval. Development of torsades de pointes is associated with higher intravenous doses of haloperidol (>35 mg i.v.) and can be triggered by disturbances of serum electrolytes levels. Prolongation of QTc interval greater than 450 ms or to greater than 25% of that in previous ECGs may warrant telemetry, cardiology consultation, and dose reduction or discontinuation. Furthermore, serum level of magnesium and potassium should be monitored during haloperidol treatment [49-52].

Although there is no approval by clinical studies low potency antipsychotic drugs (melperone, pipamperone) might help to control symptoms like anxiety and restlessness in patients with delirium. Nevertheless these drugs should be used with caution as long they have anticholinergic side effects.

**Benzodiazepines**

Available data suggest that benzodiazepine monotherapy is ineffective as treatment for general cases of delirium [21, 45]. Nevertheless, benzodiazepines are the treatment of choice for delirium tremens or for delirium due to benzodiazepine withdrawal. Furthermore, benzodiazepines are an useful alternative to neuroleptics in clinical circumstances with need for anticonvulsive medication or anticholinergic side effects or akathisia caused by neuroleptics would seriously exacerbate a patient’s condition [18]. The combination of antipsychotics and benzodiazepines decreases medication side effects and potentially increases clinical effectiveness, especially in severely ill cancer or AIDS patients [19, 21]. Adverse effects (sedation, behavioural disinhibition, amnesia, ataxia, respiratory depression, physical dependence, rebound insomnia, withdrawal reactions, and delirium) might occur, especially when using long acting benzodiazepines [53]. The risk for the development of these complications is greater in elderly patients [18]. Benzodiazepines are contraindicated in the treatment of delirium from hepatic encephalopathy, as well as in patients with respiratory insufficiency. When benzodiazepines are used, relatively short-acting medications with no active metabolites (e.g. lorazepam) should be selected, except in cases of delirium due to alcohol or sedative-hypnotic withdrawal. Doses must be carefully
considered, given the possibility that benzodiazepines may exacerbate symptoms of delirium [45].

Other Substances

Physostigmine, as a centrally cholinergic medication, has been used almost exclusively in cases of delirium clearly caused by anticholinergic medications [54]. Studies and case reports have shown that physostigmine relieves delirium caused by atropine, scopolamine, ranitidine, homatropine eye drops, benztrpine and meperidine. Possible side-effects are bradycardia, seizures, nausea, vomiting, salivation, and increased gastrointestinal and liver enzyme levels [42]. If necessary, physostigmine should be administered parenterally in doses of 2-4 mg or as a continuous infusion of 4 mg/hour [18, 55].

Deficiencies of vitamins such as nicotine amide, vitamin B and C, thiamine and folic acid can also cause delirium. In general, any alcoholic or malnourished patient with delirium should be given multivitamin replacement [18].

Patients with agitated delirium and hypercatabolic conditions (e.g., hyperdynamic heart failure, adult respiratory distress syndrome, hyperthyroid storm) which are unresponsive to other pharmacologic interventions require paralytic agent as well as mechanical ventilation and should be heavily sedated [56]. Morphine or other opiates are an important palliative treatment in cases of delirium where pain is an aggravating factor, although some opiates can exacerbate delirium through anticholinergic activity of their metabolites [53] (for a conclusion see also appendix 2).

4. CLINICAL FEATURES INFLUENCING TREATMENT

Co-Morbidity

Several comorbid psychiatric disorders are influencing treatment of delirium. Since medications for psychiatric disorders, especially antidepressants and anxiolytic drugs, can cause and exacerbate delirium, treatment of other psychiatric disorders should only be started after recovery from delirium [18].

Furthermore, depression or dementia can only be diagnosed during delirium when patient’s history reveals symptoms that clearly existed before onset of delirium, otherwise they might be misdiagnosed.

Some comorbid general medical conditions are also influencing treatment of delirium. First, patients at advanced age and especially nursing home patients have an increased risk for developing a delirium [26]. This can be caused by multiple general medical problems, polypharmacy, reduced hepatic metabolism, multisensory decline and other mental diseases, such as dementia. After conducting a careful medical evaluation, including assessment of the level of oxygenation and possible occult infections (e.g., urinary tract infections), the next step should be a screening of the patient’s medication file for drugs with potential anticholinergic effects [57, 58]. When initiating an antipsychotic medication, low doses should be used since elderly patients have a greater risk for extrapyramidal side effects and falls. However, if extrapyramidal side effects occur early in neuroleptic treatment of delirium and symptoms show fluctuations in course, Lewy body disease should be considered in differential diagnosis.

Another clinical feature influencing treatment is a hepatic disease. Impaired therapeutic effects and occurrence or increase of medication side effects can result from an altered transformation, reduced production of albumin in liver tissue and consequently raised plasma levels of medication. Some benzodiazepines, such as diazepam, require hepatic oxidation and can accumulate in patients with hepatic insufficiency. Other benzodiazepines (lorazepam, temazepam and oxazepam), and haloperidol only require glucuronidation as a major clearance pathway and should therefore be preferred in treatment of delirium in those patients [59].

Haloperidol should also be used in lower doses in AIDS patients, as those patients may have an increased sensitivity to extrapyramidal side effects [60].

Disease Management

Management of delirium includes the reduction of environmental factors that might trigger or worsen the disease or hinder recovery. Sleep wake cycle can be disturbed by intensive care unit equipment (pumps and respirators with alarms and beeps) and feeling of “timelessness” due to constant lighting can lead to overstimulation. Nonpharmacological sleep assistance (back massage, relaxation music, and warm drink at bedtime) and noise-reduction strategies (vibrating beepers, silent pill-crushers, quiet hallways, rescheduling procedures to allow sleep) help to reduce use of sedative drugs for sleep [61, 62]. It is important to provide regular amount of modest stimulation (vocal, visual, tactile). Understimulation leaves patient with his own internal disorganised perceptions and thoughts. The availability and functionality of patient's glasses or hearing aids play an important role in enabling sufficient stimulation. It also may be useful to recommend that family and friends spend time in patient's room and bring along familiar objects from home to provide orientation and feeling of security [61-63]. Early mobilization (active range-of-motions exercises three times daily, reduction of immobilizing equipment such as bladder catheters) and sufficient oral intake of fluids (including early cognition of dehydration, fluid intake protocol) reduce influence of risk factors immobility and dehydration [64]. Early and multicomponent intervention is probably most effective strategy. Once delirium has occurred, these arrangements are less effective [64].

CONCLUSION

As delirium might be life-threatening and has been shown as a prognostic factor for rise in morbidity and mortality it is necessary to identify underlying aetiologies. Furthermore immediate intervention and treatment should be paralleled by measures ensuring patient’s safety and continuous monitoring. Beside of somatic interventions treatment with high-potency neuroleptic drugs are strongly recommended. Establishing of psychological support to the patient and his family regarding illness, including post-delirium management must complete therapeutic actions.
APPENDIX 1

Evaluator: Date: 

I. Acute onset and fluctuating course

<table>
<thead>
<tr>
<th>Box 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Is there evidence of an acute change in mental status from the patient’s baseline?</td>
</tr>
<tr>
<td>b) Did the (abnormal) behaviour fluctuate during the day, that is tend to come and go or increase and decrease in severity?</td>
</tr>
</tbody>
</table>

II. Inattention

<table>
<thead>
<tr>
<th>Box 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Did the patient have difficulty focusing attention, for example, being easily distractible or having difficulty keeping track of what was being said?</td>
</tr>
</tbody>
</table>

III. Disorganized thinking

<table>
<thead>
<tr>
<th>Box 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Was the patient’s thinking disorganized or incoherent, such as rambling or irrelevant conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject?</td>
</tr>
</tbody>
</table>

IV. Altered level of consciousness

Overall, how would you rate the patient’s level of consciousness?

-- Alert (normal)

-- Vigilant (hyperalert)
-- Lethargic (drowsy, easily aroused)
-- Stupor (difficult to arouse)
-- Coma (unarousable)

Do any checks appear in this box? No Yes

If all items in Box 1 are checked and at least one item in Box 2 is checked a diagnosis of delirium is suggested.

APPENDIX 2

Choice of Specific Somatic Interventions

1. Antipsychotic medication

   a) Haloperidol
      - Initial dose 1-2 mg every 2-4 hours (adapted dose in elderly patients)
      - Administered orally, intramuscularly, or intravenously
      - Monitor ECG is required if given intravenously (QTc prolongation)

   b) Newer antipsychotic drugs (risperidone, olanzapine, quetiapine)
      - Only a few published clinical trials in delirium

2. Other interventions

   a) Benzodiazepines
      - In combination with haloperidol for alcohol/sedative-hypnotic withdrawal and in cases with prominent anxiety and agitation
      - Combined treatment with haloperidol and 0.5-1.0 mg i.v. lorazepam

   b) Cholinergics
      - For delirium caused by anticholinergic agents

   c) Opioids
      - For agitation in palliative patients with delirium in whom pain is a aggravating factor

   d) Paralysis and ventilation
      - For agitated patients with agitated delirium and severe hypercatabolic conditions

REFERENCES


The Open Critical Care Medicine Journal, 2011, Volume 4
Jochum and Bär

- The Open Critical Care Medicine Journal, 2011, Volume 4 Jochum and Bär
- Psychosomatics 2004; 45(4): 297-301.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
- American Psychiatric Association Practice Guidlines 1999; first ed. APA. Practice guidline for the treatment of patients with delirium.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
- Delirium and its treatment. CNS Drugs 2008; 22(8): 631-44.
Disease Management in Patients with Delirium


Received: January 18, 2010 Revised: March 16, 2011 Accepted: April 15, 2011

© Jochum and Bär; Licensee Bentham Open.
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.